This may already be posted, but I can't find it.
Navitoclax study looks promising for Rux resistant MF.
-One novel item of interest is an actual correlation between survival and VAF (allele burden) and/or fibrosis grade reductions with this agent:
<<"What is most notable in this analysis is the overall survival among patients who demonstrate VAF and BMF responses >>
<<VAF and BMF responses occurred despite the presence of high molecular risk mutations>>
VAF reduction of more than 20% (23% of patients) and fibrosis of at least 1 grade (38% of patients) provided the benefit.
Reductions were measured at week 24, I assume they will continue the study.
It is a dose finding study and there were a lot of AE's, so they are adjusting doses.
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
